Mutual Advisors LLC Has $8.44 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Mutual Advisors LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,603 shares of the company’s stock after purchasing an additional 406 shares during the period. Mutual Advisors LLC’s holdings in Johnson & Johnson were worth $8,437,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Family CFO Inc bought a new position in Johnson & Johnson during the fourth quarter worth $26,000. Professional Financial Advisors LLC raised its stake in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the last quarter. Joseph P. Lucia & Associates LLC bought a new stake in Johnson & Johnson in the first quarter valued at $38,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $49,000. Institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Up 0.5 %

Johnson & Johnson stock opened at $166.09 on Tuesday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market cap of $436.68 billion, a PE ratio of 24.18, a price-to-earnings-growth ratio of 3.14 and a beta of 0.59. The firm’s 50-day simple moving average is $174.04 and its 200 day simple moving average is $174.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same period in the previous year, the company earned $2.48 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.72%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Finally, Citigroup reduced their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *